The efficacy and safety of KRD and KD regimens for multiple myeloma patients:Retrospective study by Kansai Myeloma Forum
Not Applicable
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000037431
- Lead Sponsor
- Graduate School of Medicine, Kyoto University, Department of Hematology and Oncology
- Brief Summary
111 patients received KRd. The median progression-free survival (PFS) was 9.7 months. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein significantly affected PFS. 50 patients received Kd. The median PFS was 7.1 months. Based on the multivariate analysis, reduction of the carfilzomib dose and ISSIII significantly affected PFS. Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who disagree to study participation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival, Overall response rate, Adverse event